.jpg)
Aptar Pharma, a worldwide expert in drug delivery and active material science solutions and services, revealed that they have signed an exclusive partnership with PULMOTREE to oversee the advancement and marketing of their Kolibri Non-Propellant...
Efforts to replace medical inhalers with near-zero emission alternatives have advanced, as AstraZeneca announced the completion of the clinical program for a new propellant with 99.9% lower Global Warming Potential (GWP) than those used in current...
The Lung Cancer Research Foundation (LCRF) has stated that it will partner with Bayer Pharmaceuticals to provide funding for two research grants aimed at developing new approaches to enhance the understanding and treatment of lung cancers with...
The FDA has approved Strides Pharma Global, Singapore's generic theophylline extended-release tablets, 300 mg and 450 mg.The product is identical in bioavailability and therapeutic effects to the Reference Listed Drug (RLD), THEO-DUR, from...
Sun Pharma and Israel-based Moebius Medical announced that the USFDA has granted fast track designation (FTD) to their novel non-opioid therapy, MM-II, designed to address osteoarthritis knee pain. This designation allows for an expedited review p...
Acepodia, a biotech company in the clinical phase, is creating original cell therapies using its distinctive antibody-cell conjugation (ACC) and allogeneic gamma delta 2 (?d2) T cell technologies. It recently revealed a strategic clinical...
BlueRock Therapeutics LP, a company developing cell therapy in clinical stage and a subsidiary of Bayer AG, announced the FDA's approval of its IND application for OpCT-001, a treatment for primary photoreceptor diseases. BlueRock Therapeutics LP...
.jpg)
PharmaEssentia Corporation, a biopharmaceutical company from Taiwan, using expertise and scientific principles, will distribute BESREMi in Canada for treating polycythemia vera through an exclusive licensing agreement with FORUS Therapeutics Inc...
HealthPlix Technologies, the biggest AI-driven EMR software provider in India, introduced HALO, an inventive solution aimed at modernizing healthcare by converting doctor-patient interactions into digital prescriptions...
.JPG)
Nxera Pharma Co., Ltd. is set to get a US$35 million payout from Neurocrine Biosciences (‘Neurocrine’) for the Phase 2 trial success with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as disclosed on 28 August 2024. Recognition of the US$35...
, CDSCO.jpg)
